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Abstract
Mast cells are known to play a pivotal role in allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis by
releasing granules containing histamine, LTC4, and other preformed chemical mediators. Previous reports have
demonstrated that IKK2 (also called IKKb), a central intracellular component of NF-kB activation pathways, plays a critical
role in IgE-mediated degranulation of mast cells and anaphylaxis in mice. In this study, we show that protein levels of tumor
suppressor p53 are up-regulated upon IgE-mediated activation in mast cells and lack of p53 results in enhanced responses
in both early and late phase anaphylaxis. p53 inhibits not only the catalytic activity of IKK2 presumably through the
modulation of glycosylation but also p65 (RelA)-mediated transactivation. Our findings are the first to demonstrate that p53
functions as a negative regulator in mast cells.
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Introduction
Mast cells are recognized as the major effector cells of the type I
hypersensitivity reactions and they are known to play a pivotal role
in allergic diseases, such as allergic rhinitis, asthma, and atopic
dermatitis. Engagement of FceRI by IgE, followed by the
aggregation of multiple IgE-bearing FceRI molecules by polyva-
lent antigens, leads to degranulation and release of histamine,
LTC4, and other preformed chemical mediators [1,2]. Addition-
ally, multiple cytokine genes are transcribed and newly synthesized
arachidonic acid metabolites are secreted [1,2].
It is well established that mast cells promote the early phase of
type I hypersensitivity reactions by releasing granule contents after
FceRI-crosslinking. Recently, we have demonstrated that IKK2,
which is a central component of the intracellular signaling
pathway mediating NF-kB activation [3–6], plays critical roles in
IgE-mediated anaphylaxis in vivo and IgE-mediated degranula-
tion of mast cells in vitro [7]. Upon FceRI stimulation, IKK2
phosphorylates SNAP-23, the target membrane soluble N-
ethylmaleimide-sensitive fusion factor attachment protein receptor
(SNARE), leading to degranulation and anaphylactic reactions [7].
Moreover, accumulating evidence has shown that the kinase
activity of IKK2 is regulated by post-translational modifications
[6]. However, it is still unknown whether the post-translational
modifications of IKK2 are involved in IKK2-mediated degranu-
lation of mast cells and anaphylactic reactions.
Transcription factors of the NF-kB family, which consists of NF-
kB1, NF-kB2, p65 (also called RelA), c-Rel, and RelB, regulate the
expression of hundreds of genes in the context of multiple
important biological processes, such as apoptosis, proliferation,
innate and adaptive immune responses, and inflammation [3,4].
p65 has been shown to play critical roles in IKK2-mediated gene
induction of proinflammatory cytokines [3,4]. It has also been
shown that the activity of p65 is modulated by several other
molecules including CREB binding protein, glucocorticoid
receptor, and SP1 transcription factor [6]. However, the
regulatory mechanisms underling p65-mediated gene induction
of proinflammatory cytokines in mast cells are still largely
unknown.
Tumor suppressor p53 is a sequence-specific transcription factor
that is critical for maintaining genomic stability [8]. Without
cellular stresses, protein levels of p53 in cells are maintained at low
levels and the majority of p53 remains in the cytoplasm. Upon
induction of various stresses such as apoptosis, cell cycle arrest,
senescence, DNA repair, cell metabolism, and autophagy [9–12],
the half-life of p53 increases from minutes to hours. p53 then
translocates into the nucleus and activates its target genes.
Although the roles of p53 in stress-associated stimulation have
been well studied, the roles of p53 in antigen receptor-mediated
stimulation are poorly understood.
In this study, we show that the protein levels of p53 are up-
regulated upon IgE-mediated activation in mast cells and that the
lack of p53 results in enhanced mast cell activation in vivo as well
as in vitro. p53 inhibits not only the catalytic activity of IKK2
through the modulation of glycosylation but also p65-mediated
transactivation. Our findings indicate that p53 functions as a
negative regulator of mast cell activation through the inhibition of
NF-kB pathways.
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Mice
p53-deficient (p53
2/2)m i c eo naC 5 7 B L / 6b a c k g r o u n d[ 1 3 ]
were purchased from Taconic Farms (Hudson, NY). Mast cell-
deficient WBB6F1-W/W
v mice (W/W
v mice) were purchased
from SLC (Shizuoka, Japan). p65-heterozygous mice [14] were
kindly provided by Dr. Baltimore (California Institute of
Technology, USA). Mice were bred and housed in the animal
care facility at Salk Institute and Chiba University. Experimental
procedures involving mice followed the guidelines from the
National Institutes of Health and Chiba University and were
approved by the Animal Use Committee (approval ID; 09-052)
at the Salk Institute and at Chiba University (approval ID;
21-11).
Flow cytometric analysis
Cells were analyzed on FACSCalibur (Becton Dickinson, San
Jose, CA) with CELLQuest software. The following antibodies
were purchased: anti-CD117 (c-kit) allophycocyanin (APC) (2B8;
BD Biosciences, San Diego, CA) and anti-FceRIa (FITC) (MAR-
1; eBioscience, San Diego, CA). Before staining, Fc receptors were
blocked with anti-CD16/32 antibody (2.4G2; BD Biosciences).
Negative controls consisted of isotype-matched directly conjugat-
ed, nonspecific antibodies (BD Biosciences).
Histological quantification of mast cells
Peritoneal mast cells were stained with anti-CD117 (c-kit)
APC and anti-FceRIa (FITC) and analyzed by flow cytometry.
The numbers of mast cells in the tissue were counted by light
microscopy (x400) on Alcian blue-stained sections. Data were
expressed as the number of mast cells per mm
2 in ear dermis
and the number of mast cells per villus crypt unit in jejunal
mucosa.
Cell culture
Primary culture of IL-3-dependent bone marrow-derived mast
cells (BMMCs) was prepared from 6- to 8-week-old WT and
p53
2/2 mice and maintained as previously described [15].
Approximately 99% of cells recovered after 4 weeks of culture
were morphologically mast cells.
Reconstitution of mast cells in W/W
v mice with BMMCs
For reconstitution of skin mast cells in W/W
v mice, WT
BMMCs or p53
2/2 BMMCs (1610
6 cells in 20 ml of PBS) were
injected intradermally into the right ear of W/W
v mice as
described previously [7]. As controls, PBS was injected to the
left ear.
Passive cutaneous anaphylaxis
To induce passive cutaneous anaphylaxis (PCA), 4 weeks after
the transplantation of BMMCs, the mice were sensitized with
monoclonal mouse dinitrophenol-specific (anti-DNP) IgE (100 ng
in 20 ml of PBS, Sigma, St Louis, MO) by intradermal injection
into the ear. Twenty-four hours later, 200 mg of DNP-HSA
(human serum albumin; Sigma) diluted in sterile saline were
injected intravenously to the mice. Ear swelling was quantified by
three consecutive measurements of ear thickness using calipers
before (base line) and 1, 2, 3, 4, and 6 hours after the antigen
challenge. In some experiments, 0.5% Evans blue dye was injected
together with DNP-HSA. Where indicated, 2-deoxy-D-glucose (2-
DG, 50 ml of 0.2 mM/mouse) were given intravenously to the
mice at 20 hours before the antigen challenge.
Measurement of Evans blue dye extravasation
To extract Evans blue dye from the tissue, ear biopsy specimens
were incubated in 0.3 ml of formamide at 60uC for 4 days.
Absorption was measured at 620 nm as described previously [7].
Late phase allergic reactions
Four weeks after the transplantation of BMMCs to W/W
v mice,
the mice were sensitized with anti-DNP IgE (20 mg/mice)
intravenously. Twenty-four hours later, mice were challenged
with epicutaneous application of 10 ml of DNFB (0.2% wt/vol) in
acetone/olive oil (4:1) to both sides of the ears. Ear swelling was
assessed before (base line) and 2, 4, 6, 8, 12, 24, and 48 hours after
the challenge.
IgE receptor engagement
For stimulation of BMMCs via Fce receptors, cells were
incubated with mouse anti-trinitrophenol (TNP) IgE (1 mg/ml,
BD Biosciences) at 37uC for 2 hours, washed twice with PBS, and
then incubated with TNP
234-BSA (50 ng/ml, Bioresearch
Technologies, Novato, CA) at 37uC for the indicated times in
Tyrode’s buffer (130 mmol/L NaCl, 5 mmol/L KCl, 1.4 mmol/L
CaCl2, 1 mmol/L MgCl2, 5.6 mmol/L glucose, 10 mmol/L
HEPES, and 0.1% BSA, PH 7.4). In some experiments, BMMCs
were incubated with selective IKK2 inhibitor ML120B (10 mM)
[16] or vehicle (0.01% DMSO) for 1 hour prior to stimulation. For
inhibition of glycolysis, BMMCs were incubated with 2-DG (4.5
mg/ml) for 2 hours prior to stimulation. For inhibition of O-
GlcNAcylation, BMMCs were incubated with streptozotocin
(STZ; 5 mM) for 3 hours prior to stimulation.
b-hexosaminidase assay
Enzyme activity of b-hexosaminidase was evaluated for both the
supernatant and the cell lysate using p-nitrophenyl-N-acetyl b-D-
glucosamine (Sigma) as a substrate. The percentage of specific b-
hexosaminidase release was expressed as 100 x supernatant
activity/(supernatant activity + cell lysate activity) as described
previously [7].
Measurement of cytokines
BMMCs were cultured and stimulated with IgE receptor
engagement as described above. The amounts of TNF-a and IL-
6 in the culture supernatant were measured by TNF-a and IL-6
ELISA kit (BD Biosciences). The assay was performed in duplicate
according to the manufacturer’s instruction. The detection limit
was 15 pg/ml for both cytokines.
Intracellular staining of p53
BMMCs were stimulated with IgE receptor engagement or
Nutlin-3a (10 mM) for the indicated times. Cells were fixed,
permeabilized with Perm/Wash buffer (BD Biosciences), stained
with anti-p53-Alexa Fluor 647 (1C12, Cell Signaling Technology,
Denvers, MA), and analyzed by flow cytometry.
Annexin-V staining
To detect membrane fusion of BMMCs, cells were stained with
Annexin-V-PE (BD Biosciences) in Annexin-V binding buffer (BD
Biosciences) for 15 minutes and analyzed by flow cytometry.
Reporter gene assay
Expression vectors for p65 [17], IKK2SE [7], and p53 [18] and
NF-kB-reporter-construct [19] were described previously.
HEK293 cells were transiently transfected with these plasmids
using Effectene transfection reagent (Qiagen, Valencia, CA). Cells
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luciferase assay system (Promega Biotech Inc., Madison, WI).
Firefly luciferase activity of reporter constructs was normalized to
renilla luciferase activity of pRL-TK.
RNA purification and quantitative PCR (Q-PCR)
BMMCs were stimulated with IgE receptor engagement as
described above. Total RNA was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA) and reverse-transcribed into cDNA
using Super Script First-Strand Synthesis System for RT-PCR
(Invitrogen). Q-PCR was performed by ABI Prism 7700 sequence
detection system with SYBR Green PCR master mix (Applied
Biosystems, Foster City, CA) using following primer pairs:
p21
WAF1/CIP1 (sense) 59-CCTGGTGATGTCCGACCTG-39;
(antisense) 59-CCATGAGCGCATCGCAATC-39;
BAX (sense) 59-TGAAGACAGGGGCCTTTTTG-39;
(antisense) 59-AATTCGCCGGAGACACTCG-39;
TIGAR (sense) 59-CGCTTCGCCTTGACCGTTAT-39;
(antisense) 59-ACCCAGTCTCCGAAAGGGG-39;
TNF-a (sense) 59-ACAGAAAGCATGATCCGCG-39;
(antisense) 59-GCCCCCCATCTTTTGGG-39;
IL-6 (sense) 59-ACAACCACGGCCTTCCCTACTT-39;
(antisense) 59-CACGATTTCCCAGAGAACATGTG-39;
Ifit2(sense) 59-AGTACAACGAGTAAGGAGTCACT-39;
(antisense) 59-AGGCCAGTATGTTGCACACATGG-39;
Ifit3 (sense) 59-AGTGAGGTCAACCGGGAATCT-39;
(antisense) 59-TCTAGGTGCTTTATGTAGGCCA-39;
The levels of each gene were normalized to the levels of
cyclophylin A.
Immunoprecipitation and immunoblotting
Whole cell extracts were prepared and immunoblotting was
performed as described previously [20] using antisera to IKK2
(Cell Signaling Technology, Inc.), SNAP-23 (Novus Biologicals,
Littleton, CO), O-GlcNAc (Covance, Princeton, NJ), p53 (Cell
Signaling Technology, Inc.), and tubulin (Santa Cruz Biotechnol-
ogy, Inc. Santa Cruz, CA). Antiserum to phospho-SNAP-23-Ser95
was a kind gift from Dr. Roche (National Institute of Health,
Bethesda, MD). The specificity of these antibodies was described
previously [21]. Immunoprecipitations were performed using anti-
IKK2 antibodies (Cell Signaling Technology, Inc.) with Protein G
Sepharose (Amersham Biosciences, Sweden). The aliquot of lysates
was subjected to immunoblotting.
Data analysis
Data are summarized as means 6 SD. The statistical analysis of
the results was performed by the unpaired t-test. p values ,0.05
were considered significant.
Results
p53 expression is enhanced in mast cells upon
IgE-mediated stimulation
To determine the role of p53 in antigen receptor-mediated
stimulation in mast cells, we first examined the kinetics of p53
expression upon IgE-mediated stimulationin bone marrow-derived
mast cells (BMMCs). As shown in left panels of Figure 1A, IgE-
mediated stimulation increased protein levels of p53 in BMMCs.
Notably, the majority of BMMCs did not undergo apoptosis
(Figure 1A, right panels) in spite of an increase in p53 expression. In
contrast, Nutlin-3a [22], a compound that induces p53 expression
by blocking the interaction between p53 and Mdm2 [23], strongly
increased protein levels of p53 (Figure 1B, left panels) and induced
apoptosis in mast cells (Figure 1B, right panels). Western blotting
alsoshowed thatIgE-mediated stimulation increasedthe expression
of p53 in wild type (WT) BMMCs but not in p53-deficient (p53
2/2)
BMMCs (Figure 1C). Not only Nutlin-3a but also IgE-mediated
stimulation induced mRNA expression of p21
WAF1/CIP1, one of
direct targets of p53 [24], in BMMCs (Figure 1D). Importantly,
whereas Nutlin-3a induced the expression of BAX, a pro-apoptotic
target of p53 [25], but not of TIGAR, an anti-apoptotic target of
p53 [25], in BMMCs, IgE-mediated stimulation induced the
expression of TIGAR but not of BAX in BMMCs (Figure 1E–F).
PUMA, another pro-apoptotic target of p53 [26], was not induced
by IgE-mediated stimulation or Nutlin-3a (data not shown). These
results suggest that IgE-mediated stimulation induces p53 expres-
sion without the induction of apoptosis in mast cells, presumably
because of the induction of anti-apoptotic targets rather than pro-
apoptotic targets.
p53 expression is not required for the development of
mast cells
We next examined whether the development of mast cells is
affected by the lack of p53 using p53
2/2 mice. The numbers of
mast cells in the peritoneal cavity (Figure S1A), skin dermis (ear)
(Figure S1B), or jejunal mucosa (Figure S1C) were indistinguish-
able between WT mice and p53
2/2 mice. The development of
BMMCs in p53
2/2 mice was also similar to that in WT mice and
more than 98% of cells recovered after 4 weeks of culture were c-
kit positive (data not shown). The expression levels of c-kit and
FceRIa (Figure S2A) as well as morphological features (Figure
S2B) were indistinguishable between WT and p53
2/2 BMMCs.
The lack of p53 expression in BMMCs from p53
2/2 mice was
confirmed by flow cytometry (Figure S2C). These results indicate
that p53 is not required for the development of mast cells.
Lack of p53 in mast cells results in enhanced anaphylaxis
and degranulation
To assess the physiological significance of p53 up-regulation
upon IgE-mediated stimulation, we investigated the role of p53 in
IgE-mediated anaphylaxis using a mast cell knock-in system [1,2].
In this experiment, cultured p53
2/2 BMMCs or WT BMMCs
were intradermally transplanted into mast cell-deficient WBB6F1-
Kit
w/Kit
w-v (W/W
v) mice. Four weeks after the transplantation,
these mice were sensitized with DNP-specific IgE antibody and
then challenged with DNP-HSA. Importantly, W/W
v mice
reconstituted with p53
2/2 BMMCs exhibited enhanced ear
thickness (Figure 2A) and enhanced leakage of Evans blue dye
(Figure 2B–C) as compared to W/W
v mice reconstituted with WT
BMMCs. On the other hand, the numbers of mast cells in the ear
were nearly identical between W/W
v mice reconstituted with
p53
2/2 BMMCs and WT BMMCs (Figure S3). Therefore, it is
suggested that the enhanced anaphylaxis in W/W
v mice
reconstituted with p53
2/2 BMMCs is due to hyper-reactivity of
p53
2/2 mast cells to IgE-mediated stimulation.
To address the cellular basis for the enhanced anaphylaxis in
W/W
v mice reconstituted with p53
2/2 BMMCs, we next
compared IgE-mediated degranulation between p53
2/2 BMMCs
and WT BMMCs. Consistent with the enhanced anaphylaxis in
W/W
v mice reconstituted with p53
2/2 BMMCs, p53
2/2
BMMCs showed a clear increase in IgE-induced degranulation
assessed by the release of b-hexosaminidase (Figure 2D). p53
2/2
BMMCs also showed an enhanced binding to Annexin-V, which
specifically binds to phosphatidylserine that is exposed to outer
surface by degranulation in mast cells, as compared to WT
BMMCs (Figure 2E–F). These results suggest that p53 attenuates
IgE-induced degranulation in mast cells.
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activity of IKK2
Given that the phosphorylation of SNAP23 by IKK2 is a key
biological process in mast cell degranulation and early phase allergic
reactions[7],wenextexaminedwhetherp53affectsIKK2functions.
Importantly, we found a significant increase in IgE-induced
phosphorylation of SNAP23 in p53
2/2 BMMCs (Figure 3A–B).
We also examined the role of IKK2 in the enhanced degranulation
in p53
2/2 BMMCs by using an IKK2-specific inhibitor ML120B
[16,27]. The efficacy of ML120B was confirmed by its effect on
TNF-a-induced IkBa phosphorylation in WT BMMCs (Figure S4).
Consistent with our previous report [7], ML120B inhibited IgE-
induced degranulation in WT BMMCs (Figure 3C). In addition,
ML120B significantly inhibited IgE-induced degranulation in p53
2/2
BMMCs (Figure 3C) to the level similar to that in ML120B-treated
WT BMMCs (Figure 3C). Taken together, these results suggest that
IKK2 activation is likely to be involved in the increase of IgE-
induced degranulation in p53
2/2 BMMCs.
Figure 1. Upregulation of p53 expression upon IgE-mediated stimulation. (A–B) BMMCs were stimulated with IgE receptor engagement
(A)o rN u t l i n - 3 a( 1 0mM) (B) for the indicated times as described in the Methods. Cells were fixed, permeabilized, incubated with anti-p53-Alexa
Fluor 647 (filled histograms) or isotype-matched IgG (dot line), and analyzed by flow cytometry. p53 expression at 24 hours after Nutlin-3a
stimulation could not be analyzed because of apoptosis (ND; not determined). Apoptotic cells were assessed by dot plot analysis with Forward/
Side Scattering analysis (Gate R1). Shown are representative data from 5 independent experiments. (C) WT BMMCs or p53
2/2 BMMCs were
stimulated with IgE receptor engagement as described in the Methods. Before and 2, 6, and 24 hours after IgE receptor engagement, the
expression of p53 and tubulin (as a control) was analyzed by immunoblotting. Shown are representative blots from 4 independent experiments.
(D–F) BMMCs were stimulated with (black columns) or without (white columns) either IgE receptor engagement or Nutlin-3a. Four hours later,
total RNA was isolated and Q-PCR analysis was performed. The expression of p21
WAF1/CIP1 (D), BAX (E), or TIGAR (F) was normalized to the
expression of cyclophylin A. Data are means 6 SD of relative expression from 5 independent experiments. *significantly different from the mean
value of controls, *p,0.01.
doi:10.1371/journal.pone.0025412.g001
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Recently, it has been reported that the absence of p53 results in the
enhanced catalytic activity of IKK2 by causing O-GlcNAcylation at
Ser733 in fibroblasts [28,29]. We therefore examined O-GlcNAcyla-
tion of IKK2 in p53
2/2 B M M C sa n df o u n dt h a tI K K 2w a si n d e e d
O-GlcNAcylated in p53
2/2 BMMCs but not in WT BMMCs
(Figure 4A). In addition, the induction of TIGAR, which functions as
a potent inhibitor of glycolysis [25], was significantly increased in WT
BMMCs but not in p53
2/2 BMMCs upon IgE-mediated stimulation
(Figure 4B). Therefore, it is possible that p53 reduces the levels of O-
GlcNAcylation of IKK2 via the induction of TIGAR.
To determine whether O-GlcNAcylation of IKK2 in p53
2/2
BMMCs is involved in the enhanced anaphylaxis in W/W
v mice
reconstituted with p53
2/2 BMMCs (Figure 2), we investigated the
effect of 2-deoxy-D-glucose (2-DG), a glycolytic inhibitor, on IgE-
mediated anaphylaxis. As shown in Figure 4C, 2-DG inhibited IgE-
induced leakage of Evans blue dye not only in W/W
v mice
reconstituted withWTBMMCs butalso in W/W
vmice reconstituted
with p53
2/2 BMMCs. 2-DG also inhibited IgE-induced degranu-
lation of p53
2/2 BMMCs (Figure 4D). Because O-GlcNAcylation of
IKK2 has been shown to enhance its kinase activity [29], we next
examined the effect of streptozotocin (STZ), an O-GlcNAcase
inhibitor, on IgE-induced degranulation. STZ enhanced O-GlcNA-
cylation of IKK2 (Figure 4E) and enhanced IgE-induced degranu-
lation (Figure 4F) in WT BMMCs. Taken together, these results
suggest that O-GlcNAcylation of IKK2 is a possible mechanism of
the enhanced degranulation in p53
2/2 BMMCs.
p53 attenuates late phase allergic reactions and
NF-kB-mediated cytokine production
Late phase responses in IgE-mediated anaphylaxis are promot-
ed by mast cell-derived pro-inflammatory cytokines such as TNF-a
and IL-6 [1]. We next examined late phase responses in IgE-
mediated anaphylaxis in W/W
v mice reconstituted with p53
2/2
Figure 2. Lack of p53 expression in mast cells results in enhanced anaphylaxis and degranulation. (A–C) WT BMMCs or p53
2/2 BMMCs
were injected intradermally into the right ear of WBB6F1-W/W
v mice (W/W
v mice). Four weeks later, passive cutaneous anaphylaxis (PCA) was induced
as described in the Methods. Ear swelling was quantified before (base line) and 1, 2, 4, and 6 hours after antigen challenge. n=6 for each group.
*significantly different from the mean value of WT BMMCs, *p,0.01. (B) Representative photograph of leakage of injected Evans blue (EB) dye in the
ear in W/W
v mice reconstituted with p53
2/2 BMMCs or WT BMMCs. (C) Quantification of extravasated EB dye in the ear specimens. Data are means 6
SD of absorbance at 620 nm, n=6, each, *p,0.01. (D) WT BMMCs or p53
2/2 BMMCs were stimulated with (black columns) or without (white
columns) IgE receptor engagement. Degranulation was assessed by b-hexosaminidase assay. Data are means 6 SD of the percent b-hexosaminidase
release, n=6, *p,0.01. (E, F) WT BMMCs or p53
2/2 BMMCs were stimulated with or without IgE receptor engagement for 1 hour. Membrane fusion
of BMMCs was assessed by Annexin-V binding by using flow cytometry. Shown are the representative histograms of Annexin-V binding (E) and
means 6 SD of mean fluorescence intensity (M.F.I.) of Annexin-V binding (F). n=5, each, *p,0.01.
doi:10.1371/journal.pone.0025412.g002
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v mice
reconstituted with p53
2/2 BMMCs exhibited strong ear swelling
as compared with W/W
v mice reconstituted with WT BMMCs.
Consistent with strong ear swelling in W/W
v mice reconstituted
with p53
2/2 BMMCs, IgE-induced TNF-a and IL-6 secretion
was significantly facilitated in p53
2/2 BMMCs as compared with
that in WT BMMCs (Figure 5B–C). IgE-induced mRNA
induction of TNF-a and IL-6 was also facilitated in p53
2/2
BMMCs (Figure 5D–E). These results suggest that p53 inhibits
IgE-induced pro-inflammatory cytokine production in mast cells
and inhibits subsequent late phase responses in IgE-mediated
anaphylaxis.
In the NF-kB pathways, p65 directly induces the expression of a
number of target genes in a various cell types [3]. We next
examined IgE-induced expression of Ifit2 and Ifit3, whose
induction by LPS is shown to be dependent on p65 [30], in WT
BMMCs and p65-deficient (p65
2/2) BMMCs. As expected, the
induction of Ifit2 and Ifit3 by IgE-mediated stimulation was
detected in WT BMMCs but not in p65
2/2 BMMCs (Figure
S5A–B), indicating that IgE-mediated induction of Ifit2 and Ifit3 is
also dependent on p65. IKK2-specific inhibitor ML120B also
inhibited IgE-mediated induction of Ifit2 and Ifit3 in WT BMMCs
(Figure 5F–G). Consistent with the enhanced catalytic activity of
IKK2 in p53
2/2 BMMCs (Figure 3A–B), IgE-mediated induction
of Ifit2 and Ifit3 was significantly enhanced in p53
2/2 BMMCs
and ML120B inhibited IgE-mediated induction of Ifit2 and Ifit3 in
p53
2/2 BMMCs (Figure 5F–G). However, importantly, even in
the presence of ML120B, IgE-mediated induction of Ifit2 and Ifit3
was still observed in p53
2/2 BMMCs (Figure 5F–G). The residual
activity of p65-dependent transcription in ML120B-treated p53
2/2
BMMCs but not in ML120B-treated WT BMMCs suggest that
besides the inhibition of IKK2, p53 may directly regulate the
activity of p65.
To address the possibility that p53 directly inhibits the activity
of p65, we finally investigated the effect of ectopic expression of
p53 on NF-kB-dependent promoter activation induced by a
phosphomimetic mutant IKK2, IKK2SE, or by p65. As shown in
Figure 5H, p53 repressed not only IKK2SE-induced activation of
NF-kB-dependent promoter but also p65-induced activation of
NF-kB-dependent promoter, indicating that p53 directly represses
p65 activity. Taken together, these results indicate that p53
attenuates IgE-mediated expression of pro-inflammatory cytokine
genes not only by suppressing the catalytic activity of IKK2
through the modulation of glycosylation but also by suppressing
the transcriptional activity of p65.
Discussion
Inthis study,we show that p53 functions asa negative regulator of
mast cell activation through the inhibition of NF-kB pathways. We
found that protein levels of p53 were up-regulated upon IgE-
mediated stimulation in mast cells without the induction of apoptosis
(Figure 1). We also found that the lack of p53 in mast cells results in
enhanced IgE-induced degranulation (Figure 2) and cytokine
production (Figure 5), leading to enhanced responses in both early
phase (Figure 2) and late phase (Figure 5) of IgE-mediated
anaphylaxis in vivo. These results suggest that p53 is involved in
negative feedback regulation of IgE-madiated mast cell activation.
Figure 3. Lack of p53 expression in mast cells results in enhanced kinase activity of IKK2 and degranulation. (A, B) IgE-mediated
SNAP-23 phosphorylation in WT and p53
2/2 BMMCs was analyzed by immunoblotting using phosphorylation site-specific antibody. The
representative blots from 4 independent experiments (A) and means 6 SD of the density of the blots (B) are shown. *significantly different from the
mean value of WT BMMCs, *p,0.01. d.u.=density unit. (C) WT and p53
2/2 BMMCs were incubated with ML120B (10 mM) or vehicle (DMSO (0.01%)).
Sixty minutes later, IgE-mediated degranulation was assessed as described in Figure 2D. Data are means 6 SD of the percent b-hexosaminidase
release, n=5, *p,0.05. n.s.=not significant.
doi:10.1371/journal.pone.0025412.g003
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apoptosis, cell cycle arrest, and senescence, increases p53
expression, leading to apoptosis of various cell types [9–12]. In
contrast, we found that IgE-induced increase of p53 expression did
not affect mast cell survival (Figure 1A). We also found that
whereas Nutlin-3a, a compound that induces p53 expression [23],
induced the expression of a pro-apoptotic p53 target BAX but not
of an anti-apoptotic p53 target TIGAR in mast cells, IgE-mediated
stimulation induced the expression of TIGAR but not of BAX in
mast cells (Figure 1E–F). These results suggest that the balance
between a pro-apoptotic p53 target gene and an anti-apoptotic
p53 target gene could be involved in the non-apoptotic feature of
mast cells upon IgE-induced p53 expression.
The reasons why IgE-mediated stimulation induces an anti-
apoptotic p53 target TIGRR while p53 activation by Nutlin-3a
induces a pro-apoptotic p53 target BAX in mast cells are still
unclear. It is well established that Nutlin-3a induces p53
expression by blocking the interaction between p53 and Mdm2
[23]. On the other hand, although a molecular machinery of IgE-
mediated up-regulation of p53 has not been clarified, IgE-
mediated stimulation activates several signaling pathways includ-
ing PKC pathway, calcineurin/NFAT pathway, Ras/RAF/
MEK/ERK pathway, Rac/MEKK/JNK pathway, and IKK
complex/NF-kB pathway in mast cells [1]. Therefore, it is possible
that the activation of these signaling pathways by IgE-mediated
stimulation affects the balance between the expression of BAX and
TIGAR in mast cells.
Regarding the mechanism by which p53 attenuates IgE-
mediated stimulation, we show that the lack of p53 results in a
significant increase in IgE-induced phosphorylation of SNAP23 in
mast cells (Figure 3A–B), a key biological process in mast cell
degranulation and early phase allergic reactions [7]. In addition,
we found that the inhibition of IKK2, which phosphorylates
SNAP23 upon IgE-mediated stimulation in mast cells [7],
cancelled the enhanced IgE-induced degranulation in p53
2/2
BMMCs (Figure 3C), suggesting that IKK2-mediated phosphor-
ylation of SNAP23 is involved in the enhanced IgE-induced
degranulation in p53
2/2 mast cells. Moreover, the expression of
TIGAR, which functions as a potent inhibitor of glycolysis [25],
was significantly increased in WT BMMCs but not in p53
2/2
Figure 4. Lack of p53 expression in mast cells results in enhanced O-GlcNAcylation of IKK2. (A) O-GlcNAcylation of IKK2 in WT or p53
2/2
BMMCs was detected by immunoprecipitation with anti-IKK2 antibody, followed by immunoblotting with anti-O-GlcNAc antibody. Shown are
representative blots from 5 independent experiments. (B) The expression of TIGAR was assessed by Q-PCR analysis as described in Figure 1F. Data
are means 6 SD, n=5, *significantly different from the mean value of controls, *p,0.01. (C) 2-deoxy-D-glucose (2-DG) were given to W/W
v mice
reconstituted with WT or p53
2/2 BMMCs. Twenty hours later, PCA reaction was assessed as described in Figure 2C. Data are means 6 SD, n=6 for
each, *p,0.05. (D) WT or p53
2/2 BMMCs were incubated with 2-DG (4.5 mg/ml) for 2 hours. IgE-mediated degranulation was assessed as described
in Figure 2D. Data are means 6 SD of the percent b-hexosaminidase release, n=5, *p,0.01. (E) WT BMMCs were incubated with streptozotocin
(STZ; 5 mM) or vehicle for 3 hours. O-GlcNAcylation of IKK2 was detected as described in Figure 4A. Shown are representative blots from 5
independent experiments. (F) After incubation with STZ for 3 hours, WT BMMCs were subjected to IgE-mediated degranulation. Data are means 6 SD
of the percent b-hexosaminidase release, n=5, *significantly different from the mean value of vehicle, *p,0.05.
doi:10.1371/journal.pone.0025412.g004
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25412Figure 5. p53 attenuates late phase allergic reactions and NF-kB-mediated cytokine production. (A) W/W
v mice were reconstituted with
WT or p53
2/2 BMMCs and late phase allergic reactions were induced as described in the Methods. Data were means 6 SD of IgE-mediated increase
in ear thickness, n=6 for each genotype, *significantly different from the mean value of WT BMMCs, *p,0.01. (B–E) WT or p53
2/2 BMMCs were
stimulated with (black columns) or without (white columns) IgE receptor engagement. (B, C) The levels of TNF-a and IL-6 in the supernatants were
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more, Kawauchi et al. have recently shown that the absence of
p53 results in the enhanced catalytic activity of IKK2 by causing
O-GlcNAcylation in fibroblasts [29]. Taken together, these results
raise the possibility that IgE-mediated stimulation induces the
expression of TIGAR through the induction of p53 and
subsequently TIGAR reduces the levels of O-GlcNAcylated
IKK2, leading to the attenuation of IgE-mediated degranulation
and cytokine production in mast cells.
We found that O-GlcNAcylation of IKK2 was detected in p53
2/
2 BMMCs but not in WT BMMCs (Figure 4A). We also found that
2-DG inhibited IgE-induced degranulation in p53
2/2 BMMCs but
not in WT BMMCs (Figure 4D). These results suggest that O-
GlcNAcylation of IKK2 is almost completely inhibited by the
presence ofp53inWTBMMCs.Incontrasttotheseinvitrostudies,
2-DG treatment inhibited IgE-mediated leakage of Evans blue dye
in W/W
v mice reconstituted not only with p53
2/2 BMMCs but
with WT BMMCs (Figure 4C). The discrepancy raises the
possibility that the inhibition of O-GlcNAcylation of IKK2 by
p53 is incomplete in mast cells in the in vivo studies. It is also
possible that the glycolytic modification of some signaling molecule
besides IKK2 is involved in IgE-mediated increase of vascular
permeabilityintheinvivostudies. Furtherexperimentsarerequired
to address these possibilities.
In conclusion, the evidence provided here suggests that p53
plays a crucial role in controlling the intensity and/or duration of
mast cell responses to antigens by suppressing IgE receptor-IKK2-
NF-kB axis at multiple steps.
Supporting Information
Figure S1 The numbers of mast cells in the tissues are
indistinguishable between WT mice and p53
2/2 mice.
The numbers of mast cells in the peritoneal cavity (A), skin dermis
(ear) (B), and jejunal mucosa (C) were evaluated as described in the
Methods. Data are means 6 SD from 5 independent
experiments. vcu=villus crypt unit.
(TIF)
Figure S2 Development of IL-3-dependent bone mar-
row-derived mast cells (BMMCs) is normal in p53
2/2
mice. (A) Bone marrow cells from WT mice or p53
2/2 mice were
cultured in the presence of IL-3 for 4 weeks. Cells were stained
with anti-FceRIa FITC and anti-c-kit APC and analyzed by flow
cytometry. Shown are representative FACS profiles from five
independent experiments. (B) BMMCs stained with Wright-
Giemsa solution are shown. (C) p53 expression in WT BMMCs
and p53
2/2 BMMCs was evaluated by flow cytometry.
(TIF)
Figure S3 The numbers of mast cells in the ear skin
dermis are indistinguishable between W/W
v mice
reconstituted with WT BMMCs and p53
2/2 BMMCs.
Four weeks after the transplantation of BMMCs, the numbers of
mast cells in the ear skin dermis were assessed.
(TIF)
Figure S4 Selective IKK2 inhibitor ML120B inhibits
phosporylation of IkBa. (A, B) BMMCs were incubated with
ML120B (10 mM) or vehicle (DMSO (0.01%)) as a control for 60
minutes and then stimulated with or without TNF-a (10 ng/ml).
Fifteen minutes later, cell lysates were recovered and analyzed by
immunoblot analysis using phosphorylation site-specific antibod-
ies. Representative blots from five independent experiments (A)
and means 6 SD of the density of blots (B) were shown.
*significantly different from the mean value of vehicle, *p,0.01.
d.u.=density unit.
(TIF)
Figure S5 IgE-induced Ifit2 and Ifit3 expression is p65
dependent. (A, B) WT BMMCs or p65
2/2 BMMCs were
stimulated with or without IgE receptor engagement. Two hours
later, total RNA was extracted and Q-PCR for Ifit2 (A) or Ifit3 (B)
was performed. Data are means 6 SD of relative expression from
5 independent experiments. *significantly different from the mean
value of controls, *p,0.01.
(TIF)
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